Clinical Trial Update: A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IBR854 plus pazopanib versus pazopanib alone in advanced renal cell carcinoma; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IBR854
• Pazopanib (Pazopanib)

Snippet

Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. | Conditions: Renal Cell Carcinoma (RCC) | Phase 2 | Status: NOT_YET_RECRUITING